BR112023022836A2 - Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso - Google Patents
Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu usoInfo
- Publication number
- BR112023022836A2 BR112023022836A2 BR112023022836A BR112023022836A BR112023022836A2 BR 112023022836 A2 BR112023022836 A2 BR 112023022836A2 BR 112023022836 A BR112023022836 A BR 112023022836A BR 112023022836 A BR112023022836 A BR 112023022836A BR 112023022836 A2 BR112023022836 A2 BR 112023022836A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- glp
- pharmaceutical compositions
- benzimidazoyl
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 BENZIMIDAZOYL Chemical class 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183612P | 2021-05-03 | 2021-05-03 | |
| US202163282686P | 2021-11-24 | 2021-11-24 | |
| PCT/US2022/027535 WO2022235717A1 (en) | 2021-05-03 | 2022-05-03 | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022836A2 true BR112023022836A2 (pt) | 2024-01-16 |
Family
ID=81750835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022836A BR112023022836A2 (pt) | 2021-05-03 | 2022-05-03 | Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220396569A1 (enExample) |
| EP (2) | EP4334304A1 (enExample) |
| JP (1) | JP2024516291A (enExample) |
| AU (1) | AU2022271223A1 (enExample) |
| BR (1) | BR112023022836A2 (enExample) |
| CA (1) | CA3217720A1 (enExample) |
| MX (1) | MX2023012918A (enExample) |
| WO (1) | WO2022235717A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230074486A (ko) * | 2020-08-21 | 2023-05-30 | 테른스 파마슈티칼스, 인크. | Glp-1r 효능제로서의 화합물 |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| FI4408840T3 (fi) | 2021-09-27 | 2025-11-04 | Terns Pharmaceuticals Inc | Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina |
| IL312364A (en) | 2021-10-25 | 2024-06-01 | Luehr Gary W | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US12410163B2 (en) | 2022-02-23 | 2025-09-09 | Terns Pharmaceuticals, Inc. | Compounds as GLP-IR agonists |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| WO2024026338A1 (en) * | 2022-07-27 | 2024-02-01 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| EP4619098A1 (en) | 2022-11-16 | 2025-09-24 | Eli Lilly and Company | Glucagon-like peptide 1 receptor agonists |
| CN116217522B (zh) * | 2023-02-22 | 2025-06-24 | 广东莱佛士制药技术有限公司 | Glp-1受体激动剂关键中间体的手性纯化方法 |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
| WO2026073030A1 (en) | 2024-09-27 | 2026-04-02 | Carmot Therapeutics Inc. | Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| US20120021979A1 (en) | 2010-06-24 | 2012-01-26 | Vanderbilt University | GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction |
| CN110325530B (zh) * | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| BR112021020335A2 (pt) * | 2019-04-12 | 2021-12-14 | Qilu Regor Therapeutics Inc | Agonistas glp-1r e usos dos mesmos |
| US12611401B2 (en) * | 2019-05-20 | 2026-04-28 | Pfizer Inc. | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| MA57692B1 (fr) * | 2019-11-15 | 2025-04-30 | Ildong Pharmaceutical Co., Ltd. | Agoniste du récepteur glp-1 et son utilisation |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
-
2022
- 2022-05-03 EP EP22725069.3A patent/EP4334304A1/en active Pending
- 2022-05-03 WO PCT/US2022/027535 patent/WO2022235717A1/en not_active Ceased
- 2022-05-03 CA CA3217720A patent/CA3217720A1/en active Pending
- 2022-05-03 US US17/736,070 patent/US20220396569A1/en not_active Abandoned
- 2022-05-03 BR BR112023022836A patent/BR112023022836A2/pt unknown
- 2022-05-03 MX MX2023012918A patent/MX2023012918A/es unknown
- 2022-05-03 EP EP24203388.4A patent/EP4461355A3/en not_active Withdrawn
- 2022-05-03 AU AU2022271223A patent/AU2022271223A1/en not_active Abandoned
- 2022-05-03 US US18/558,647 patent/US20240262811A1/en active Pending
- 2022-05-03 JP JP2023567973A patent/JP2024516291A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3217720A1 (en) | 2022-11-10 |
| JP2024516291A (ja) | 2024-04-12 |
| US20220396569A1 (en) | 2022-12-15 |
| WO2022235717A1 (en) | 2022-11-10 |
| AU2022271223A1 (en) | 2023-11-02 |
| EP4461355A2 (en) | 2024-11-13 |
| MX2023012918A (es) | 2024-03-13 |
| US20240262811A1 (en) | 2024-08-08 |
| EP4461355A3 (en) | 2025-01-15 |
| EP4334304A1 (en) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023015045A2 (pt) | Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso | |
| EP4461355A3 (en) | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | |
| BR112022007612A2 (pt) | Inibidores de raf quinases | |
| MX2021005012A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr. | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
| BR112022012637A2 (pt) | Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1 | |
| BR112023020219A2 (pt) | Anticorpos anti-il-2r agonistas e métodos de uso | |
| BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
| GT200500307A (es) | Compuestos quimicos | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BR112018067923A2 (pt) | métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3 | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
| CO2020009524A2 (es) | Formulación de adenovirus del grupo b | |
| MY208400A (en) | Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof | |
| CO2021010697A2 (es) | Formulación de anticuerpos terapéuticos | |
| BR112019010903A2 (pt) | estrutura de cristal de gremlin-1 e anticorpo inibidor | |
| CO2023006790A2 (es) | Anticuerpos de cadena pesada que se unen al receptor de folato alfa | |
| BR112022011321A2 (pt) | Compostos, polímeros, dispositivos e seus usos | |
| CO2022006466A2 (es) | Inhibidores de egfr alostéricos y métodos de uso de los mismos | |
| BRPI0511420A (pt) | fosforodiamidatos de sulfoniletila | |
| BR112022019110A2 (pt) | Dosagem qw de compostos peptídicos agonistas do receptor de gip e seus usos | |
| BR112022018586A2 (pt) | Derivados de ácido borônico e usos terapêuticos dos mesmos | |
| BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis |